HTA Quarterly | Winter 2022

The UK Innovative Medicines Fund (IMF) allows earlier market access than conventional pathways for non-cancer drugs, but what is meant by innovative, how does it work, and where does it apply?

Establishment of the Danish Medicines Council (DMC) in 2017 was intended to ensure transparent assessment of hospital medicines and rapid, consistent access to effective medicines across Denmark, while balancing healthcare costs against demand. Five years later, we consider what impact the DMC has had on market access and implications for drug developers.

Years of scrutiny of the pharmaceutical market in the US have resulted in significant drug pricing reforms. The reforms are part of the recently passed Inflation Reduction Act (IRA), enacted into law in August 2022.1 The wide-ranging IRA materially changes drug-pricing policy in the US, affecting stakeholders across the pharmaceutical supply chain. In this article, we clarify the key provisions of the IRA and offer ideas for how biopharma companies can achieve their goals in light of the new policies.